Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

The market shrugged off Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) weak earnings report. Despite the strength in the stock, we feel that investors should be cautious about some numbers in the earnings.

View our latest analysis for Hubei Biocause Heilen Pharmaceutical

A Closer Look At Hubei Biocause Heilen Pharmaceutical's Earnings

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. The ratio shows us how much a company's profit exceeds its FCF.

That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.

For the year to September 2024, Hubei Biocause Heilen Pharmaceutical had an accrual ratio of 0.37. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of free cashflow in that time. In the last twelve months it actually had negative free cash flow, with an outflow of CN¥104m despite its profit of CN¥106.3m, mentioned above. We saw that FCF was CN¥53m a year ago though, so Hubei Biocause Heilen Pharmaceutical has at least been able to generate positive FCF in the past. However, that's not all there is to consider. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Hubei Biocause Heilen Pharmaceutical.

How Do Unusual Items Influence Profit?

Given the accrual ratio, it's not overly surprising that Hubei Biocause Heilen Pharmaceutical's profit was boosted by unusual items worth CN¥20m in the last twelve months. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. Hubei Biocause Heilen Pharmaceutical had a rather significant contribution from unusual items relative to its profit to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

Our Take On Hubei Biocause Heilen Pharmaceutical's Profit Performance

Summing up, Hubei Biocause Heilen Pharmaceutical received a nice boost to profit from unusual items, but could not match its paper profit with free cash flow. For the reasons mentioned above, we think that a perfunctory glance at Hubei Biocause Heilen Pharmaceutical's statutory profits might make it look better than it really is on an underlying level. So while earnings quality is important, it's equally important to consider the risks facing Hubei Biocause Heilen Pharmaceutical at this point in time. To help with this, we've discovered 3 warning signs (2 are significant!) that you ought to be aware of before buying any shares in Hubei Biocause Heilen Pharmaceutical.

Our examination of Hubei Biocause Heilen Pharmaceutical has focussed on certain factors that can make its earnings look better than they are. And, on that basis, we are somewhat skeptical. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.